Cargando…
Hypocalcemia in a Patient With Metastatic Prostate Cancer From Denosumab Treatment
Denosumab is a humanized monoclonal antibody that binds RANKL to inhibit osteoclast activity. It is indicated for the prevention of skeletal-related events (SRE) in patients with solid tumors who have bone metastasis and in patients with multiple myeloma. Hypocalcemia is one of the known side effect...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Cureus
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427738/ https://www.ncbi.nlm.nih.gov/pubmed/34522524 http://dx.doi.org/10.7759/cureus.17046 |